US drug regulators have turned down Ipsen's effort to slow down generic competition for its blockbuster drug Somatuline Depot ...

The company has two Phase 3 data releases for Paltusotine in treating acromegaly over the next 7-8 months. Acromegaly is a disorder caused by excess levels of growth hormone, and current ...

Although the medical condition acromegaly may be fairly rare, for those who do live with the hormone disorder, it can cause a ...

Crinetics just released initial data from its phase 2 open-label study using its drug Atumelnant. Read why I'm bullish on ...

The approval includes multiple strengths of Lanreotide injection, a therapeutic equivalent generic version of Somatuline Depot Injection.

He's a great guy, and it's unfortunate that he didn't live very long. It's sad that he had that [acromegaly] disease.

Drug major Cipla on Wednesday said it has received approval from the US health regulator to market a generic medication used ...

Cipla's Lanreotide injection is indicated for the treatment of patients with Acromegaly and Gastroenteropancreatic ...

The wholly-owned subsidiary Cipla USA Inc has received the final approval for the Abbreviated New Drug Application (ANDA) of ...

Keep abreast with the latest news related to Acromegaly there are 48 news items on Acromegaly that covers updates, breakthroughs and in-depth reports. We provide you with a free downloadable ...

Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions ...

SAN DIEGO, May 22, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) a clinical stage pharmaceutical company focused on the discovery, ...